Journal of Bacteriology, December 2000, p. 6958-6963, Vol. 182, No. 24
0021-9193/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
-D-Glucopyranoside
Deacetylase (MshB) Is a Key Enzyme in Mycothiol Biosynthesis
Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093,1 and Department of Medicine, University of British Columbia, Vancouver, British Columbia V5Z 3J5, Canada2
Received 19 June 2000/Accepted 19 September 2000
| |
ABSTRACT |
|---|
|
|
|---|
Mycothiol is a novel thiol produced only by actinomycetes and is
the major low-molecular-weight thiol in mycobacteria. Mycothiol was
previously shown to be synthesized from
1-D-myo-inosityl-2-amino-2-deoxy-
-D-glucopyranoside by ligation with cysteine followed by acetylation. A novel
mycothiol-dependent detoxification enzyme, mycothiol conjugate amidase,
was recently identified in Mycobacterium smegmatis and
shown to have a homolog, Rv1082, in Mycobacterium
tuberculosis. In the present study we found that a protein
encoded by the M. tuberculosis open reading frame Rv1170, a
homolog of Rv1082, possesses weak mycothiol conjugate amidase activity
but shows substantial deacetylation activity with
1-D-myo-inosityl-2-acetamido-2-deoxy-
-D-glucopyranoside (GlcNAc-Ins), a hypothetical mycothiol biosynthetic precursor. The
availability of this protein enabled us to develop an assay for
GlcNAc-Ins, which was used to demonstrate that GlcNAc-Ins is
present in M. smegmatis at a level about twice
that of mycothiol. It was shown that GlcNAc-Ins is absent in
mycothiol-deficient mutant strain 49 of M. smegmatis and
that this strain can concentrate GlcNAc-Ins from the medium and
convert it to mycothiol. This demonstrates that GlcNAc-Ins is a key
intermediate in the pathway of mycothiol biosynthesis. Assignment of
Rv1170 as the gene coding the deacetylase in the M. tuberculosis genome represents the first identification of a gene
of the mycothiol biosynthesis pathway. The presence of a large cellular
pool of substrate for this enzyme suggests that it may be important in
regulating mycothiol biosynthesis.
| |
INTRODUCTION |
|---|
|
|
|---|
Most gram-positive bacteria,
including many strict aerobes, do not produce glutathione (7,
13), a key component of cellular mechanisms for protection
against oxygen toxicity (5). In the search for other thiols
in these organisms that might function like glutathione, a major thiol
in streptomycetes was discovered (14) and later identified
(12, 19, 21) as a novel conjugate of
N-acetylcysteine (AcCys) and
1-D-myo-inosityl-2-amino-2-deoxy-
-D-glucopyranoside (GlcN-Ins) producing mycothiol (MSH or AcCys-GlcN-Ins).
Bornemann et al. (3) showed that chemically synthesized
GlcN-Ins could be converted to Cys-GlcN-Ins and MSH
by Mycobacterium smegmatis cell extracts in the presence of
ATP, Mg2+, Cys, and acetate or acetyl coenzyme A
(acetyl-CoA). They proposed that the final steps of MSH biosynthesis
involve ATP-dependent ligation of Cys with GlcN-Ins, followed
by acetylation via an acetyltransferase reaction involving acetyl-CoA.
Measurements of GlcN-Ins and Cys-GlcN-Ins levels in
M. smegmatis (1) and isolation of mutants
defective in GlcN-Ins or Cys-GlcN-Ins production support the existence of this pathway (15).
The earlier studies left undefined the biochemical reactions involved
in GlcN-Ins formation. By analogy with the established biochemistry for production of the glycosylphosphatidylinositol (GPI) anchor, which contains as a component an isomer of
GlcN-Ins with an
(1-6) linkage, one might expect that
GlcN-Ins is produced by deacetylation of
1-D-myo-inosityl-2-acetamido-2-deoxy-
-D-glucopyranoside (GlcNAc-Ins) and that the latter is produced by transfer of
GlcNAc from UDP-GlcNAc to Ins (6). We
present here evidence that GlcNAc-Ins is an intermediate in MSH
biosynthesis and is converted to GlcN-Ins by GlcNAc-Ins
deacetylase. This deacetylase cleaves an amide bond similar to that
hydrolyzed by an MSH-dependent detoxification enzyme,
mycothiol S-conjugate amidase, recently identified as being coded by
Rv1082 in the Mycobacterium tuberculosis genome (11). We show here that Rv1170, a homolog of Rv1082, codes
for a GlcNAc-Ins deacetylase activity involved in the MSH
biosynthesis pathway.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Reagents. MSH was isolated from M. smegmatis and derivatized with monobromobimane to form the MSH bimane derivative (MSmB), which was purified by high-performance liquid chromatography (HPLC), all as previously described (12). Purified M. smegmatis mycothiol S-conjugate amidase was used to quantitatively hydrolyze MSmB to stereochemically pure GlcN-Ins, and the latter was purified from the other hydrolysis product, AcCySmB, using a Sep-Pak C18 (Waters) cartridge as previously described (11). A 10 mM stock solution of GlcNAc-Ins was prepared by addition of a tenfold excess of acetic anhydride (Fisher) to 10 mM GlcN-Ins in 10 mM NaHCO3 over 20 min while adjusting the pH to 8.5 with NaOH. The reaction was monitored for GlcN-Ins loss as described below to insure that the reaction was complete and that no residual GlcN-Ins was present. This stock solution of GlcNAc-Ins was assayed as described below and used without further purification.
Bacterial stains and culture conditions. M. smegmatis mc2155 was obtained from W. R. Jacobs, Jr. (Albert Einstein College of Medicine, Bronx, N.Y.) and cultured at 37°C in Middlebrook 7H9 medium supplemented with 0.5% Tween 80 (Fisher) and 0.4% glucose. M. smegmatis mutant 49 is an MSH-deficient mutant derived from mc2155 by chemical mutagenesis and was cultured in Middlebrook 7H9 medium at 37°C as previously described (15).
Assay of MSH and MSH precursors. MSH and its precursors (cysteine, GlcN-Ins, and Cys-GlcN-Ins) were assayed as described elsewhere (1).
Mycothiol S-conjugate amidase assay. Mycothiol S-conjugate amidase activity was assayed at 30°C using 30 µM MSmB in 50 mM HEPES (pH 7.0) containing 3 mM 2-mercaptoethanol. The formation of AcCySmB from MSmB was analyzed by HPLC (11).
Cloning and expression of the Rv1170 gene from M. tuberculosis.
Genomic DNA of M. tuberculosis
H37Rv was prepared as described previously (2). The open
reading frame Rv1170 was amplified from this DNA with the primers
5'-TAGCCATGGTGTCTGAGACGCCGCG-3' and
5'-GGATCCCGCGGTGAAGCCCAGAC-3' containing NcoI and
BamHI restriction sites, respectively. PCR was performed
with Taq polymerase obtained from Gibco BRL, using 1.5 mM
MgCl2 and 5% dimethyl sulfoxide. The 30 cycles of PCR
included denaturation at 94°C for 40 s, annealing at 55°C for
1 min, and amplification at 72°C. The PCR products were separated on
a 1% agarose gel. The appropriate PCR product was ligated into vector
pCR2.1 of the TA cloning kit (Invitrogen) and transformed into
Escherichia coli DH5
by standard chemical transformation
procedures. Clones containing the vector were selected on plates of
Luria-Bertani (LB) agar (20) plus ampicillin (100 µg/ml),
and plasmid DNA was digested with the restriction endonucleases NcoI and BamHI (Fermentas). Restriction
enzyme-digested plasmids were isolated with a QIAquick gel extraction
kit (Qiagen Ltd.). A corresponding digestion was applied to the plasmid
pET-22b, and the two products were ligated together with T4 DNA ligase to obtain the plasmid pYA1170. In order to express Rv1170 in E. coli without the pelB leader sequence, the gene from
pYA1170 was excised using NcoI and Bpu1102I
(Fermentas) and ligated to an aliquot of pET16b cut with
NcoI and Bpu1102I to generate the plasmid pYA1170b (Fig. 1). This plasmid was
transformed by the heat shock method (20) to competent
E. coli BL21(DE3) prepared according to the
CaCl2 method (20) and plated on LB agar
containing 100 µg of ampicillin/ml. Single colonies were inoculated
into 5 ml of LB broth also containing ampicillin (100 µg/ml). After
overnight incubation at 37°C with shaking, the individual cultures
were diluted 1:100 in the same medium and incubation was continued at
37°C with shaking. Isopropyl-
-D-thiogalactopyranoside
was added to a final concentration of 0.4 mM when the
A600 reached 0.6, and incubation was continued
overnight at 25°C before harvesting by centrifugation at
5,000 × g for 15 min at room temperature. The pellets
were lysed by sonication. Proteins were separated by centrifugation
(15,000 × g, 4°C, 30 min) into soluble and insoluble fractions. Total proteins were separated by sodium dodecyl
sulfate-7.5% polyacrylamide gel electrophoresis (SDS-PAGE) and
stained with Coomassie blue or transferred to polyvinylidene difluoride
membranes (Bio-Rad). The N-terminal amino acid sequence was verified
using Edman degradation after separation of samples by SDS-PAGE and electroblotting to a polyvinylidene difluoride membrane.
|
Assay of GlcNAc-Ins.
The assay of GlcNAc-Ins
involves deacetylation of the glucosamine moiety prior to labeling of
the free amine with AccQ-Fluor (Waters). Recombinant M. tuberculosis Rv1170 in crude extracts of E. coli
described above was found to have such activity. E. coli
BL21(DE3) carrying the pYA1170b expression plasmid was cultured at
37°C in LB broth with 100 µg of ampicillin/ml to an
A600 of 0.6. Isopropyl-
-D-thiogalactopyranoside was added until it
reached a concentration of 0.4 mM, and the culture was incubated
overnight at 28°C. The bacterial cell pellet was suspended in 50 mM
HEPES (pH 7.0) containing 3 mM 2-mercaptoethanol and a 35 µM
concentration of each of the protease inhibitors
N-
-p-tosyl-L-phenylalanylchloromethyl ketone and
N-
-p-tosyl-L-lysinechloromethyl
ketone and was then disrupted by sonication. The extract was clarified
by centrifugation at 39,000 × g for 30 min at 4°C.
Saturated ammonium sulfate was added to the supernatant until it
reached 20% by volume, the mixture was allowed to stand 1 h on
ice, and the supernatant was clarified by centrifugation. The ammonium
sulfate was added until 50% saturation was attained, and the mixture
was stored overnight at 4°C. The 20 to 50% ammonium sulfate pellet
was collected by centrifugation at 39,000 × g for 30 min at 4°C. This protein pellet (0.69 g) was suspended in 10 ml of
the extraction buffer, and the insoluble material was removed by
centrifugation at 39,000 × g for 30 min at 4°C. The
supernatant was dialyzed overnight at 4°C against 100 volumes of
extraction buffer. The supernatant was concentrated in a Millipore
UltraFree-15 50-kDa nominal-molecular-weight cutoff centrifugal filter
to ~80 mg of protein per ml. This preparation was frozen in aliquots
at
70°C and used as needed for deacetylation of GlcNAc-Ins.
Uptake and metabolism of GlcNAc-Ins by mutant 49. M. smegmatis MSH-deficient mutant 49 (15) was cultured in 7H9 Middlebrook medium with 0.4% glucose and 0.5% Tween 80 to log phase (A600 = 0.6), and 10-ml aliquots were transferred to sterile 25-ml Erlenmeyer flasks. Duplicate flasks contained cells only (control), 20 µM myo-inositol, 20 µM glucosamine, 20 µM N-acetylglucosamine, or 17 µM GlcNAc-Ins and were cultured at 37°C and 225 rpm. Samples (~2.3 × 108 cells) were taken at 2, 6, 19, and 46 h of culture. The cells were pelleted by centrifugation for 2 min at 14,000 × g and were extracted in 50% acetonitrile containing 20 mM HEPES (pH 8.0) and either 2 mM monobromobimane for thiol analysis or 5 mM NEM for amine analysis and thiol control samples. Duplicate cultures were analyzed for GlcN-Ins, GlcNAc-Ins, Cys-GlcN-Ins, cysteine, and MSH. No significant MSH was found in any sample except for the cultures supplemented with GlcNAc-Ins.
The concentration dependence of the uptake of GlcNAc-Ins was examined with cultures of M. smegmatis mutant 49. Mutant 49 was cultured at 37°C for 23 h in 5 ml of 7H9 Middlebrook medium as described above, supplemented with 0, 4, 8, or 21 µM GlcNAc-Ins. The cells were collected by centrifugation and extracted for amine and thiol analysis as described above.UDP-GlcNAc-Ins:inositol GlcNAc transferase assay.
Late-log-phase M. smegmatis mc2155 cells (1 g
[wet weight]) were extracted by sonication in 5 ml of 50 mM HEPES (pH
7.0) containing 3 mM 2-mercaptoethanol and a 35 µM concentration of
each of the protease inhibitors
N-
-p-tosyl-L-phenylalanylchloromethyl
ketone and
N-
-p-tosyl-L-lysinechloromethyl
ketone. The unfractionated extract was dialyzed against 100 volumes of
the extraction buffer for 7 h, all at 4°C. The extract was
assayed for formation of GlcN-Ins at 30°C after mixing the
dialyzed extract sample with an equal volume of buffer concentrate to
give a content of 50 mM HEPES (pH 7.0), 25 mM KCl, 5 mM
MnCl2, 5 mM MgCl2, 3 mM 2-mercaptoethanol, and
1 mM ATP. Stock solutions (5 mM) of UDP-GlcNAc (Sigma) and myo-inositol (Sigma) were prepared in water. The extract was
assayed for GlcNAc-Ins deacetylase activity with 0.1 mM
GlcNAc-Ins as the substrate. The assay of transferase activity was
conducted by mixing 2 µl each of 5 mM UDP-GlcNAc and 5 mM
myo-inositol stock solutions with 100 µl of extract and
treating the mixture as one would for the deacetylase assay. Aliquots
(20 µl) were removed and mixed with 20 ml of 5 mM NEM in 50% aqueous
acetonitrile at 60°C. The mixture was incubated at 60°C for 10 min
and centrifuged, and 15-µl aliquots were analyzed for
GlcN-Ins as previously described (1). Duplicate
samples were analyzed at 0- and 2-h reaction intervals.
| |
RESULTS |
|---|
|
|
|---|
M. smegmatis amidase lacks deacetylase activity.
Mycothiol S-conjugate amidase from M. smegmatis, a homolog
of the protein encoded by M. tuberculosis Rv1082, cleaves
the amide bond linking Cys to GlcN in MSH derivatives having an
alkylated sulfur residue (11), and it seemed possible that
this enzyme might also cleave the corresponding bond in GlcNAc-Ins,
functioning as a deacetylase (Fig. 2). To
test this, we prepared GlcNAc-Ins from GlcN-Ins and
compared the ability of the amidase purified from M. smegmatis to hydrolyze GlcNAc-Ins with its ability to cleave
the monobromobimane conjugate of MSH (MSmB). For a test with 100 µM
substrate, the activity measured with MSmB was 4.5 ± 1.0 µmol
min
1 mg of protein
1 (11),
whereas that measured with GlcNAc-Ins was <1 nmol
min
1 mg of protein
1 (n = 4). Thus, the amidase does not exhibit measurable deacetylase activity and cannot serve this function in the MSH biosynthesis pathway
of M. smegmatis.
|
Rv1170 encodes a protein with GlcNAc-Ins deacetylase activity. Since the deacetylase and the amidase both cleave an amide bond involving glucosamine, we reasoned that these proteins might be related. We therefore searched the Sanger Centre database for homologs of the 288-amino-acid M. tuberculosis amidase, Rv1082. The closest homolog found was Rv1170, with a length of 304 residues and 36% identity to Rv1082 with homology throughout the sequence. M. tuberculosis open reading frame Rv1170 was PCR cloned and expressed in E. coli by using the expression vector pET16b (Fig. 1). Figure 3 shows that the 20 to 50% saturated ammonium sulfate fraction from E. coli carrying the Rv1170 gene contains elevated levels of a protein of the expected size (36 kDa), as compared to those from E. coli prepared with a blank cloning vector. Another, smaller protein (~26 kDa) was also present at elevated levels and is speculated to be a degradation product of the deacetylase. The identity of the 36-kDa protein was confirmed by determining the N-terminal amino acid sequence and finding it identical to that predicted for the protein encoded by open reading frame Rv1170.
Enzyme activity was determined on the 20 to 50% ammonium sulfate fractions after desalting and concentrating (Table 1). Extract from cells expressing Rv1170 exhibited substantial deacetylase activity with GlcNAc-Ins as the substrate, over 300-fold greater than the deacetylase activity determined with GlcNAc and 23-fold greater than the amidase activity measured with MSmB (Fig. 2). Thus, Rv1170 can be putatively identified as the GlcNAc-Ins deacetylase gene in the MSH biosynthesis pathway of M. tuberculosis.
|
|
Assay for GlcNAc-Ins. To confirm that GlcNAc-Ins is present in mycobacteria, an assay for this component was needed. The availability of cloned Rv1170 allowed the development of such an assay. Cell extracts were prepared in warm 50% acetonitrile containing NEM, as employed previously for an assay of GlcN-Ins (1). One portion of the extract was assayed directly for GlcN-Ins content, while a second portion was assayed after treatment with a preparation of expressed Rv1170 under conditions sufficient to convert all GlcNAc-Ins to GlcN-Ins. The difference in these two assay results yields the GlcNAc-Ins content for the sample. In most cases, GlcN-Ins levels are at least an order of magnitude lower than those of GlcNAc-Ins, so this method gives reliable results. Values are reported as micromoles per gram of residual dry weight (RDW) determined on the residue from the 50% acetonitrile extract. The relationship between A600 and RDW was determined for aliquots of mc2155 cells producing ~30 mg of RDW and found to be 0.42 ± 0.02 mg of RDW per ml of cells with an A600 at 1.00. No variation of >15% in this value was seen between log- and stationary-phase cells.
The method was tested with extracts prepared from log-phase cells of mutant 49 by spiking the extract with GlcNAc-Ins at levels equivalent to 0.13 and 0.013 µmol per g of RDW. The recoveries from triplicate determinations were 97% ± 5% and 132% ± 3%, respectively. At the lowest level of added GlcNAc-Ins, a significant correction had to be applied for background peaks present in unspiked controls which overlapped the GlcN-Ins peak. The greater-than-100% recovery found for the samples spiked at the lowest level indicates that this correction produces a systematic error and thus defines the lower limit of useful sensitivity for this assay.M. smegmatis mc2155 produces
GlcNAc-Ins, but MSH-deficient mutant 49 does not.
M.
smegmatis mc2155 cells were examined in exponential
and stationary phases for their content of MSH and its precursors
(Table 2). M. smegmatis
accumulates GlcNAc-Ins to a substantial level, almost twice the MSH
content. The GlcN-Ins content was very much lower in log phase
and declined further in stationary phase, as had been observed
previously (1). When mutant 49 was examined in analogous
fashion, the levels of MSH and its precursors were below the limits of
detection (see Table 3; [GlcNAc-Ins] = 0). The absence of
GlcNAc-Ins in mutant 49 shows that it is defective in an initial
step of MSH biosynthesis.
|
Extracts of M. smegmatis and mutant 49 have deacetylase
activity.
If the deacetylase is involved in MSH biosynthesis and
if mutant 49 is blocked at an earlier step in the pathway, then strains mc2155 and 49 should both produce deacetylase activity.
Centrifuged extracts of exponentially growing cells were assayed in
duplicate for GlcN-Ins production with and without the addition
of 100 µM GlcNAc-Ins. The background rate for production of
GlcN-Ins measured without added GlcNAc-Ins was high for
strain mc2155 (6.1 ± 0.1 pmol min
1 mg
of protein
1), presumably reflecting the substantial
endogenous level of GlcNAc-Ins present in the undialyzed extract.
Addition of 100 µM GlcNAc-Ins increased the rate to 19.7 ± 0.4 pmol min
1 mg of protein
1, giving a net
rate increase of 13.6 ± 0.5 pmol min
1 mg of
protein
1. For mutant 49, which does not contain
GlcNAc-Ins, the background rate was <0.06 pmol
min
1 mg of protein
1, and the rate with 100 µM GlcNAc-Ins was 16.4 ± 1.4 pmol min
1
mg of protein
1. Thus, the deacetylase activity of strain
49 is essentially the same as that of the parent strain.
MSH-deficient mutant 49 can import GlcNAc-Ins and utilize it to
synthesize MSH.
The foregoing results imply that mutant 49 should
be able to synthesize MSH if supplied with GlcNAc-Ins. When mutant
49 was grown in media supplemented with GlcNAc-Ins and the cells
were analyzed for their content of MSH and MSH precursors, the results established that GlcNAc-Ins is imported and utilized for MSH
biosynthesis (Table 3). Levels of MSH and
its precursors were found to increase with increasing concentrations of
GlcNAc-Ins added to the growth medium. In another experiment, we
measured cellular GlcN-Ins, GlcNAc-Ins, cysteine, and MSH
levels for strain 49 as a function of growth in medium containing 17 µM GlcNAc-Ins (Fig. 4). Cellular cysteine levels remained unchanged at 0.36 ± 0.08 µmol per g of RDW over the experiment. Cells contained 2.9 µmol per g of RDW of
GlcNAc-Ins at the first measurement (2 h), which corresponds to a
level approaching millimolar. This occurred prior to the appearance of
significant GlcN-Ins in the cell, showing that strain 49 is
able to import and concentrate GlcNAc-Ins intact prior to its
deacetylation. The level of GlcNAc-Ins appeared to fall at 6 h
before rising to an even higher level in stationary phase.
|
|
Failure to detect GlcNAc-Ins production from UDP-GlcNAc and
Ins.
To test whether UDP-GlcNAc could transfer GlcNAc to
myo-inositol to produce GlcNAc-Ins, we examined a
dialyzed, uncentrifuged, cell extract of M. smegmatis
mc2155 for evidence of GlcNAc-Ins formation from these
precursors. The extract was assayed for the production of
GlcN-Ins from 0.1 mM GlcNAc-Ins, and 22 ± 1 pmol
min
1 mg of protein
1 of GlcNAc-Ins
deacetylase activity was found. Thus, if GlcNAc-Ins were formed
in our assay mixtures, it would be deacetylated by endogenous
GlcNAc-Ins deacetylase to GlcN-Ins and assayed as the free
amine. When extracts were analyzed for the production of GlcN-Ins from 0.1 mM UDP-GlcNAc and 0.1 mM
myo-inositol, GlcN-Ins formation was less than 0.4 pmol min
1 mg of protein
1.
| |
DISCUSSION |
|---|
|
|
|---|
The results presented here further elaborate the pathway involved
in MSH biosynthesis. The final two steps
in the pathway were postulated by Bornemann et al. (3) to
involve the ATP-dependent ligation of Cys with GlcN-Ins to
produce Cys-GlcN-Ins, followed by transacetylation of the
latter by acetyl-CoA, as shown in Fig. 5. The present studies
demonstrate that GlcNAc-Ins is the major intracellular MSH
component in M. smegmatis and is converted to GlcN-Ins by GlcNAc-Ins deacetylase. This defines what
we propose as the second step in MSH biosynthesis. Assignment of Rv1170
as the gene coding for the deacetylase in the M. tuberculosis genome represents the first gene of the MSH
biosynthesis pathway to be identified. Assuming that GlcNAc-Ins is
produced by a single enzyme, we propose that the genes for the MSH
biosynthesis pathway be designated mshA,
mshB, mshC, and mshD, with the corresponding enzymes labeled as shown in Fig. 4. Identification of
mshA, mshC, and mshD would be greatly
simplified if they were clustered with mshB in a single
operon, but inspection of the gene assignments and open reading frames
surrounding mshB (Rv1170) in the M. tuberculosis genome (4) indicates that this is not the case.
|
All mycobacteria thus far examined have high MSH content (10) and are expected to have an ortholog of the MSH biosynthesis enzyme MshB (Rv1170). The available unfinished mycobacterial genome databases yield homologs close to Rv1170 for Mycobacterium leprae (Sanger Centre), Mycobacterium bovis (Sanger Centre), M. tuberculosis CDC1551 (The Institute for Genomic Research [TIGR]), M. smegmatis (TIGR), and Mycobacterium avium (TIGR). This indicates that MSH biosynthesis in these organisms utilizes a GlcNAc-Ins deacetylase (MshB) in the same manner as that described here for M. smegmatis. Other actinomycetes that produce MSH are also expected to have a GlcNAc-Ins deacetylase (MshB) gene homologous to Rv1170.
Sequence BLAST searches using the Rv1170 sequence also produced M. tuberculosis homolog Rv1082 (mycothiol conjugate amidase) and the Rv1082 orthologs from M. leprae (Sanger Centre), M. bovis (Sanger Centre), M. tuberculosis CDC1551 (TIGR), M. smegmatis (TIGR), and M. avium (TIGR) as the closest homologs. Sequences with partial homology to Rv1170 were also found in the yeast, rat, and human genome databases. These genes code for PIG-L, the second enzyme in GPI anchor biosynthesis (9), and catalyze the deacetylation of N-acetylglucosaminyl-phosphatidylinositol (GlcNAc-PI). One sequence near the amino-terminal portion of Rv1170, VXAHPDDE, is conserved throughout and is a candidate for the catalytic site based upon the functional similarity of these enzymes. Although the substrate structures differ, all of the these enzymes hydrolyze a C2-amide bond of glucosamine in various disaccharide substrates containing the glucosaminyl-inositol moiety.
Rv1170 (mshB) is the fourth gene of MSH metabolism to be identified. The first was for MSH-dependent formaldehyde dehydrogenase of Amycolatopsis methanolica (8, 16), whose protein sequence is 80% identical to Rv2259 of M. tuberculosis (Sanger Centre). A disulfide reductase (Rv2855) initially designated as a glutathione reductase (4) was cloned and expressed in M. smegmatis and was shown to have specificity for mycothiol disulfide, alternatively designated mycothione (17, 18). The mycothiol S-conjugate amidase gene (Rv1082, mca) was the third gene identified (11), making its homolog GlcNAc-Ins deacetylase (Rv1170, mshB) the fourth.
The results indicate that the deacetylase is rather specific for GlcNAc-Ins and is not a broad-spectrum deacetylase. Removing the Ins residue from the substrate resulted in a more than 300-fold decrease in reactivity (GlcNAc-Ins versus GlcNAc) (Table 1 and Fig. 2). Also, no deacetylation activity was detected with MSH or MSmB as substrates (Table 1), so the AcCys moiety of MSH (Fig. 2) is inert to the deacetylase. This shows that the deacetylase has no significant activity for the degradation of MSH. A more complete evaluation of the substrate specificity of the deacetylase must await its purification to homogeneity.
The deacetylase appears to be the control point for MSH biosynthesis.
Thus, there is a very large endogenous pool of its substrate, GlcNAc-Ins (12 to 15 µmol per g of RDW) (Table 2), but quite low
levels of its product, GlcN-Ins (
0.2 µmol per g
of RDW) (Table 2), and of the final intermediate, Cys-GlcN-Ins,
(<0.006 µmol per g of RDW) leading to MSH. This suggests that
substantial quantities of MSH can be produced upon demand from the
endogenous pool of GlcNAc-Ins under control of the deacetylase
(MshB). Exactly how the activity of the deacetylase is controlled is
not clear and will be explored in future studies with the purified enzyme.
Tests for GlcNAc transferase activity producing GlcNAc-Ins with UDP-GlcNAc and myo-inositol as substrates did not yield measurable activity. This suggests that the route to GlcNAc-Ins in mycobacteria may not be analogous to that followed in eucaryotic GPI anchor biosynthesis. Alternatively, the reaction may require some specialized conditions not yet identified. Thus, the detailed nature of the first step of MSH biosynthesis remains to be established.
| |
ACKNOWLEDGMENTS |
|---|
We thank Mary Ko for technical assistance.
This work was supported by grants to R.C.F. from the National Institute of Alcoholism and Alcohol Abuse (AA11393), the National Institute of Allergy and Infectious Diseases (AI49174), the National Science Foundation (MCB-998150), and the Fogarty International Center (TW00976). Research by Y.A.-G. at the University of British Columbia was supported by the British Columbia Lung Association and the TB Veterans Association.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093-0506. Phone: (619) 534-2163. FAX: (619) 534-4864. E-mail: rcfahey{at}ucsd.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Anderberg, S.,
G. L. Newton, and R. C. Fahey.
1998.
Mycothiol biosynthesis and metabolism: cellular levels of potential intermediates in the biosynthesis and degradation of mycothiol.
J. Biol. Chem.
273:30391-30397 |
| 2. |
Av-Gay, Y.,
S. Jamil, and S. J. Drews.
1999.
Expression and characterization of the Mycobacterium tuberculosis serine/threonine protein kinase PknB.
Infect. Immun.
67:5676-5682 |
| 3. | Bornemann, C., M. A. Jardine, H. S. C. Spies, and D. J. Steenkamp. 1997. Biosynthesis of mycothiol: elucidation of the sequence of steps in Mycobacterium smegmatis. Biochem. J. 325:623-629. |
| 4. | Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, C. E. Barry III, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, A. Krogh, J. McLean, S. Moule, L. Murphy, K. Oliver, J. Osborne, M. A. Quail, M.-A. Rajandream, J. Rogers, S. Rutter, K. Seeger, J. Skelton, R. Squares, S. Squares, J. E. Sulston, K. Taylor, S. Whitehead, and B. G. Barrell. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544[CrossRef][Medline]. |
| 5. | Dolphin, D., R. Poulson, and O. Avramovic. 1989. Glutathione: chemical, biochemical, and medical aspects, parts A and B. John Wiley & Sons, Inc., New York, N.Y. |
| 6. | Englund, P. T. 1993. The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors. Annu. Rev. Biochem. 62:121-138[CrossRef][Medline]. |
| 7. |
Fahey, R. C.,
W. C. Brown,
W. B. Adams, and M. B. Worsham.
1978.
Occurrence of glutathione in bacteria.
J. Bacteriol.
133:1126-1129 |
| 8. | Misset-Smits, M., P. W. van Ophem, S. Sakuda, and J. A. Duine. 1997. Mycothiol, 1-O-(2'-[N-acetyl-L-cysteinyl]amido-2'-deoxy-alpha-D-glucopyranosyl)-D-myo-inositol, is the factor of NAD/factor-dependent formaldehyde dehydrogenase. FEBS Lett. 409:221-222[CrossRef][Medline]. |
| 9. |
Nakamura, N.,
N. Inoue,
R. Watanabe,
M. Takahashi,
J. Takeda,
V. L. Stevens, and T. Kinoshita.
1997.
Expression cloning of PIG-L, a candidate N-acetylglucosaminyl-phosphatidylinositol deacetylase.
J. Biol. Chem.
272:15834-15840 |
| 10. |
Newton, G. L.,
K. Arnold,
M. S. Price,
C. Sherrill,
S. B. delCardayré,
Y. Aharonowitz,
G. Cohen,
J. Davies,
R. C. Fahey, and C. Davis.
1996.
Distribution of thiols in microorganisms: mycothiol is a major thiol in most actinomycetes.
J. Bacteriol.
178:1990-1995 |
| 11. | Newton, G. L., Y. Av-Gay, and R. C. Fahey. 2000. A novel mycothiol-dependent detoxification pathway in mycobacteria involving mycothiol S-conjugate amidase. Biochemistry 39:10739-10746[CrossRef][Medline]. |
| 12. | Newton, G. L., C. A. Bewley, T. J. Dwyer, R. Horn, Y. Aharonowitz, G. Cohen, J. Davies, D. J. Faulkner, and R. C. Fahey. 1995. The structure of U17 isolated from Streptomyces clavuligerus and its properties as an antioxidant thiol. Eur. J. Biochem. 230:821-825[Medline]. |
| 13. | Newton, G. L., and R. C. Fahey. 1989. Glutathione in procaryotes, p. 69-77. In J. Viña (ed.), Glutathione: metabolism and physiological functions. CRC Press, Boca Raton, Fla. |
| 14. |
Newton, G. L.,
R. C. Fahey,
G. Cohen, and Y. Aharonowitz.
1993.
Low-molecular-weight thiols in streptomycetes and their potential role as antioxidants.
J. Bacteriol.
175:2734-2742 |
| 15. |
Newton, G. L.,
M. Unson,
S. Anderberg,
J. A. Aguilera,
N. N. Oh,
S. delCardayré,
Y. Av-Gay, and R. C. Fahey.
1999.
Characterization of Mycobacterium smegmatis mutants defective in 1-D-myo-inosityl-2-amino-2-deoxy- -D-glucopyranoside and mycothiol biosynthesis.
Biochem. Biophys. Res. Commun.
255:239-244[CrossRef][Medline].
|
| 16. |
Norin, A.,
P. W. Van Ophem,
S. R. Piersma,
B. Persson,
J. A. Duine, and H. Jornvall.
1997.
Mycothiol-dependent formaldehyde dehydrogenase, a prokaryotic medium-chain dehydrogenase/reductase, phylogenetically links different eukaroytic alcohol dehydrogenases primary structure, conformational modelling and functional correlations.
Eur. J. Biochem.
248:282-289[Medline].
|
| 17. | Patel, M. P., and J. S. Blanchard. 1999. Expression, purification, and characterization of Mycobacterium tuberculosis mycothione reductase. Biochemistry 38:11827-11833[CrossRef][Medline]. |
| 18. | Patel, M. P., and J. S. Blanchard. 1998. Synthesis of des-myo-inositol mycothiol and demonstration of a mycobacterial specific reductase activity. J. Am. Chem. Soc. 120:11538-11539[CrossRef]. |
| 19. |
Sakuda, S.,
Z.-Y. Zhou, and Y. Yamada.
1994.
Structure of a novel disulfide of 2-(N-acetylcysteinyl)amido-2-deoxy- -D-glucopyranosyl-myo-inositol produced by Streptomyces sp.
Biosci. Biotech. Biochem.
58:1347-1348[Medline].
|
| 20. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 21. | Spies, H. S., and D. J. Steenkamp. 1994. Thiols of intracellular pathogens. Identification of ovothiol A in Leishmania donovani and structural analysis of a novel thiol from Mycobacterium bovis. Eur. J. Biochem. 224:203-213[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Appl. Environ. Microbiol. | Infect. Immun. | Eukaryot. Cell |
|---|---|---|
| Mol. Cell. Biol. | J. Virol. | Microbiol. Mol. Biol. Rev. |
| ALL ASM JOURNALS |